October 23, 2023Open Access

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Key Points

Key points are not available for this paper at this time.

Abstract

Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Passaro et al. (Mon,) studied this question.

synapsesocial.com/papers/69d97dbfc7f0c3ae80a3daf8 https://doi.org/https://doi.org/10.1016/j.annonc.2023.10.117

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,515 citations
2EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis2022 · 1 citations
3P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)2021 · 7 citations
4A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors2016 · 283 citations
5Risk factors for venous thromboembolism (VTE) among patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.2023 · 12 citations

AI से पूछें

Bookmark

View Full Paper